Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Nurix Therapeutics, Inc.
Study ID
NCT06717269
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • NX-5948 — DRUG
    Administered orally in tablet or capsule form
  • Esomeprazole — DRUG
    Administered orally in capsule form

Study Details

This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

Key Dates

Start date
Nov 30, 2024
Status verified
Feb 2026
Primary completion
Apr 30, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
18 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NX-5948 tablet and capsule under fasted and fed conditions
  • Experimental: NX-5948 tablet and capsule combined with esomeprazole under fasted conditions

Primary Outcome Measure

Assessment of PK parameters: NX-5948 tablets versus capsules [ Time Frame: 9 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CelerionLincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies